A Phase IA/IB Trial to Evaluate the Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) With Hemagglutinin Dose Escalation Compared to Non-Adjuvanted Comparator Inactivated Influenza Vaccine (IIV) Standard Dose (SD) in Healthy Adults and High Dose (HD) IIV in Ambulatory Elderly Subjects

Trial Profile

A Phase IA/IB Trial to Evaluate the Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) With Hemagglutinin Dose Escalation Compared to Non-Adjuvanted Comparator Inactivated Influenza Vaccine (IIV) Standard Dose (SD) in Healthy Adults and High Dose (HD) IIV in Ambulatory Elderly Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs MER 4101 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Nova Immunotherapeutics Limited
  • Most Recent Events

    • 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 26 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 08 Oct 2017 Results (n=72) assessing safety and tolerance of MAS-1 adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted comparator IIV standard dose (SD) in healthy adults and high dose (HD) IIV in ambulatory elderly subjects, were presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top